FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293491638> ?p ?o ?g. }

• W4293491638 endingPage "100211" @default.
• W4293491638 startingPage "100211" @default.
• W4293491638 abstract "Heterologous prime-boost SARS-CoV-2 vaccination is a widely accepted strategy during the COVID-19 pandemic, which generated a superior immune response than homologous vaccination strategy.To describe immunogenicity of heterologous prime-boost vaccination with inactivated vaccine, CoronaVac, followed by BNT162b2 and 5-month booster dose with BNT162b2 in healthy Thai adolescents.Adolescents aged 12-18 years were randomized 1:1:1:1 to receive CoronaVac (SV) followed by BNT162b2 (PZ) 30 or 20 µg at either 3- or 6-week interval (SV3w/PZ30µg, SV3w/PZ20µg, SV6w/PZ30µg or SV6w/PZ20µg). During the Omicron-predominant period, participants were offered a BNT162b2 booster dose 30, 15, or 10 µg. Immunogenicity was determined using IgG antibody against spike-receptor-binding domain of wild type(anti-S-RBD IgG) and surrogate virus neutralization test(sVNT) against Delta variant at 14 days and 5 months after the 2nd dose. Neutralization tests(sVNT and pseudovirus neutralization test; pVNT) against Omicron strain were tested pre- and 14 days post-booster dose.In October 2021, 76 adolescents with a median age of 14.3 years (IQR 12.7-16.0) were enrolled: 20 in SV3w/PZ30µg; 17 in SV3w/PZ20µg; 20 in SV6w/PZ30µg; 19 in SV6w/PZ20µg. At day 14, the geometric mean(GM) of anti-S-RBD IgG in SV3w/PZ30µg was 4713 (95 %CI 4127-5382) binding-antibody unit (BAU)/ml, while geometric mean ratio(GMR) was 1.28 (1.09-1.51) in SV6w/PZ30µg. The GMs of sVNT against Delta variants at day 14 among participants in SV3w/PZ30µg and SV6wk/PZ30µg arm were 95.3 % and 99.7 %inhibition, respectively. At 5 months, GMs of sVNT against Delta variants in SV3w/PZ30µg were significantly declined to 47.8 % but remained at 89.0 % inhibition among SV6w/PZ30µg arm. In April 2022, 52 adolescents received a BNT162b2 booster dose. Proportion of participants with sVNT against Omicron strain > 80 %inhibition was significantly increased from 3.8 % pre-booster to 67 % post-booster. Proportion of participants with pVNT ID50 > 185 was 42 % at 14 days post 2nd dose and 88 % post booster, respectively.Heterologous prime-boost vaccination with CoronaVac followed by BNT162b2 induced high neutralizing titer against SARS-CoV-2 Delta strain. After 5-month interval, booster with BNT162b2 induced high neutralizing titer against Omicron strain.Thai Clinical Trials Registry (thaiclinicaltrials.org): TCTR20210923012." @default.
• W4293491638 created "2022-08-29" @default.
• W4293491638 creator A5002130311 @default.
• W4293491638 creator A5019386757 @default.
• W4293491638 creator A5023591398 @default.
• W4293491638 creator A5053556851 @default.
• W4293491638 creator A5056689889 @default.
• W4293491638 creator A5060229282 @default.
• W4293491638 creator A5069591511 @default.
• W4293491638 creator A5070748655 @default.
• W4293491638 creator A5072100122 @default.
• W4293491638 creator A5085649190 @default.
• W4293491638 date "2022-12-01" @default.
• W4293491638 modified "2023-10-18" @default.
• W4293491638 title "Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents" @default.
• W4293491638 cites W3025631553 @default.
• W4293491638 cites W3044482768 @default.
• W4293491638 cites W3087924281 @default.
• W4293491638 cites W3164720238 @default.
• W4293491638 cites W3173690790 @default.
• W4293491638 cites W3174017401 @default.
• W4293491638 cites W3202027258 @default.
• W4293491638 cites W3214683919 @default.
• W4293491638 cites W3217279957 @default.
• W4293491638 cites W4200469237 @default.
• W4293491638 cites W4205412981 @default.
• W4293491638 cites W4210747912 @default.
• W4293491638 cites W4210792795 @default.
• W4293491638 cites W4211086777 @default.
• W4293491638 cites W4211242522 @default.
• W4293491638 cites W4212998649 @default.
• W4293491638 cites W4213427867 @default.
• W4293491638 cites W4214628111 @default.
• W4293491638 cites W4220655835 @default.
• W4293491638 cites W4220925428 @default.
• W4293491638 cites W4221022322 @default.
• W4293491638 cites W4225268815 @default.
• W4293491638 cites W4225291621 @default.
• W4293491638 cites W4225575973 @default.
• W4293491638 cites W4226229183 @default.
• W4293491638 cites W4280496488 @default.
• W4293491638 cites W4280615675 @default.
• W4293491638 cites W4283367577 @default.
• W4293491638 doi "https://doi.org/10.1016/j.jvacx.2022.100211" @default.
• W4293491638 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36059600" @default.
• W4293491638 hasPublicationYear "2022" @default.
• W4293491638 type Work @default.
• W4293491638 citedByCount "3" @default.
• W4293491638 countsByYear W42934916382022 @default.
• W4293491638 countsByYear W42934916382023 @default.
• W4293491638 crossrefType "journal-article" @default.
• W4293491638 hasAuthorship W4293491638A5002130311 @default.
• W4293491638 hasAuthorship W4293491638A5019386757 @default.
• W4293491638 hasAuthorship W4293491638A5023591398 @default.
• W4293491638 hasAuthorship W4293491638A5053556851 @default.
• W4293491638 hasAuthorship W4293491638A5056689889 @default.
• W4293491638 hasAuthorship W4293491638A5060229282 @default.
• W4293491638 hasAuthorship W4293491638A5069591511 @default.
• W4293491638 hasAuthorship W4293491638A5070748655 @default.
• W4293491638 hasAuthorship W4293491638A5072100122 @default.
• W4293491638 hasAuthorship W4293491638A5085649190 @default.
• W4293491638 hasBestOaLocation W42934916381 @default.
• W4293491638 hasConcept C104317684 @default.
• W4293491638 hasConcept C116675565 @default.
• W4293491638 hasConcept C121332964 @default.
• W4293491638 hasConcept C12590561 @default.
• W4293491638 hasConcept C126322002 @default.
• W4293491638 hasConcept C1276947 @default.
• W4293491638 hasConcept C14086860 @default.
• W4293491638 hasConcept C159047783 @default.
• W4293491638 hasConcept C159654299 @default.
• W4293491638 hasConcept C185592680 @default.
• W4293491638 hasConcept C203014093 @default.
• W4293491638 hasConcept C203165030 @default.
• W4293491638 hasConcept C22070199 @default.
• W4293491638 hasConcept C2522874641 @default.
• W4293491638 hasConcept C2779134260 @default.
• W4293491638 hasConcept C2780115692 @default.
• W4293491638 hasConcept C2780801004 @default.
• W4293491638 hasConcept C2780868878 @default.
• W4293491638 hasConcept C3006700255 @default.
• W4293491638 hasConcept C3007834351 @default.
• W4293491638 hasConcept C3008058167 @default.
• W4293491638 hasConcept C524204448 @default.
• W4293491638 hasConcept C55493867 @default.
• W4293491638 hasConcept C71924100 @default.
• W4293491638 hasConceptScore W4293491638C104317684 @default.
• W4293491638 hasConceptScore W4293491638C116675565 @default.
• W4293491638 hasConceptScore W4293491638C121332964 @default.
• W4293491638 hasConceptScore W4293491638C12590561 @default.
• W4293491638 hasConceptScore W4293491638C126322002 @default.
• W4293491638 hasConceptScore W4293491638C1276947 @default.
• W4293491638 hasConceptScore W4293491638C14086860 @default.
• W4293491638 hasConceptScore W4293491638C159047783 @default.
• W4293491638 hasConceptScore W4293491638C159654299 @default.
• W4293491638 hasConceptScore W4293491638C185592680 @default.
• W4293491638 hasConceptScore W4293491638C203014093 @default.
• W4293491638 hasConceptScore W4293491638C203165030 @default.

• next